Cooperating gene mutations in acute myeloid leukemia: a review of the literature - PubMed (original) (raw)
Review
doi: 10.1038/leu.2008.19. Epub 2008 Feb 21.
Affiliations
- PMID: 18288131
- DOI: 10.1038/leu.2008.19
Review
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
A Renneville et al. Leukemia. 2008 May.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great variability in clinical course and response to therapy, as well as in the genetic and molecular basis of the pathology. Major advances in the understanding of leukemogenesis have been made by the characterization and the study of acquired cytogenetic abnormalities, particularly reciprocal translocations observed in AML. Besides these major cytogenetic abnormalities, gene mutations also constitute key events in AML pathogenesis. In this review, we describe the contribution of known gene mutations to the understanding of AML pathogenesis and their clinical significance. To gain more insight in this understanding, we clustered these alterations in three groups: (1) mutations affecting genes that contribute to cell proliferation (FLT3, c-KIT, RAS, protein tyrosine standard phosphatase nonreceptor 11); (2) mutations affecting genes involved in myeloid differentiation (AML1 and CEBPA) and (3) mutations affecting genes implicated in cell cycle regulation or apoptosis (P53, NPM1). This nonexhaustive review aims to show how gene mutations interact with each other, how they contribute to refine prognosis and how they can be useful for risk-adapted therapeutic management of AML patients.
Similar articles
- Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Schlenk RF, et al. N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306. N Engl J Med. 2008. PMID: 18450602 - Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Green CL, et al. J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439648 - Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T. Bienz M, et al. Clin Cancer Res. 2005 Feb 15;11(4):1416-24. doi: 10.1158/1078-0432.CCR-04-1552. Clin Cancer Res. 2005. PMID: 15746041 - Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD, Bullinger L. Baldus CD, et al. Semin Oncol. 2008 Aug;35(4):356-64. doi: 10.1053/j.seminoncol.2008.04.006. Semin Oncol. 2008. PMID: 18692686 Review. - Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Pedersen-Bjergaard J, et al. Leukemia. 2006 Nov;20(11):1943-9. doi: 10.1038/sj.leu.2404381. Epub 2006 Sep 21. Leukemia. 2006. PMID: 16990778 Review.
Cited by
- PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia.
Carlock C, Bai Y, Paige-Hood A, Li Q, Nguele Meke F, Zhang ZY. Carlock C, et al. JCI Insight. 2023 Oct 9;8(19):e170065. doi: 10.1172/jci.insight.170065. JCI Insight. 2023. PMID: 37665633 Free PMC article. - The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients.
Park MN. Park MN. Int J Mol Sci. 2023 Jul 27;24(15):12037. doi: 10.3390/ijms241512037. Int J Mol Sci. 2023. PMID: 37569414 Free PMC article. Review. - The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?
Haghi A, Mohammadi Kian M, Salemi M, Eghdami MR, Nikbakht M. Haghi A, et al. Int J Hematol Oncol Stem Cell Res. 2022 Oct 1;16(4):250-263. doi: 10.18502/ijhoscr.v16i4.10883. Int J Hematol Oncol Stem Cell Res. 2022. PMID: 36883106 Free PMC article. Review. - Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.
Rosli AA, Azlan A, Rajasegaran Y, Mot YY, Heidenreich O, Yusoff NM, Moses EJ. Rosli AA, et al. Clin Exp Med. 2023 Aug;23(4):1137-1159. doi: 10.1007/s10238-022-00913-1. Epub 2022 Oct 13. Clin Exp Med. 2023. PMID: 36229751 Review. - Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Döhner H, et al. Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293. Blood. 2022. PMID: 35960871 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous